Q&A with new Medical Director of TapImmune (TPIV), Dr. Richard Kenney

From MicrocapResearch.com – Researching The Best Microcap Stocks
May 10, 2017 - 8:30am
TapImmune (TPIV) is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. The company‚Äôs next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved… Continue reading → The post Q&A with new Medical Director of TapImmune (TPIV), Dr. Richard Kenney appeared first on MicrocapResearch.com - Researching The Best Microcap Stocks.


Continue reading this article »